| Bioactivity | GSK2556286 (GSK286) is an orally active inhibitor of M. tuberculosis. GSK2556286 inhibits growth within human macrophages (IC50 = 0.07 μM). GSK2556286 is effective against both multidrug-resistant (MDR) or extensively drug-resistant (XDR) and drug-sensitive (DS) M. tuberculosis[1]. | ||||||||||||
| Target | IC50: 0.07 μM (human macrophage) | ||||||||||||
| Name | GSK2556286 | ||||||||||||
| CAS | 1210456-20-4 | ||||||||||||
| Formula | C18H23N3O3 | ||||||||||||
| Molar Mass | 329.39 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Nuermberger EL, et al. GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment. Antimicrob Agents Chemother. 2022 May 24:e0013222. |
GSK2556286
CAS: 1210456-20-4 F: C18H23N3O3 W: 329.39
GSK2556286 (GSK286) is an orally active inhibitor of M. tuberculosis. GSK2556286 inhibits growth within human macrophage
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.